吏곸옣�븫�쓽 �닔�닠 �쟾 �솕�븰諛⑹궗�꽑�슂踰� �썑 �삎�깭怨꾩륫 蹂��솕�� 諛붿씠�삤留덉빱 諛쒗쁽�쓣 �씠�슜�븳 蹂묐━�븰�쟻 �셿�쟾愿��빐 �삁痢� �끂紐④렇�옩 by �뿀�쁺
  
저작자표시-비영리-변경금지 2.0 대한민국 
이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 
l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.  
다음과 같은 조건을 따라야 합니다: 
l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건
을 명확하게 나타내어야 합니다.  
l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.  
저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 
이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다.  
Disclaimer  
  
  
저작자표시. 귀하는 원저작자를 표시하여야 합니다. 
비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 
변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. 
Nomogram for Prediction of Pathologic 
Complete Remission Using 
Morphometric Change and Biomarker 
Expression in Rectal Cancer After 
Preoperative Chemoradiotherapy
Hyuk Hur
Department of Medicine
The Graduate School, Yonsei University
Nomogram for Prediction of Pathologic 
Complete Remission Using 
Morphometric Change and Biomarker 
Expression in Rectal Cancer After 
Preoperative Chemoradiotherapy
Directed by Professor Nam Kyu Kim
Doctoral Dissertation
submitted to the Department of Medicine
the Graduate School of Yonsei University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
Hyuk Hur
December 2016
This certifies that the Doctoral 
Dissertation of Hyuk Hur is approved. 
------------------------------------
Thesis Supervisor : Nam Kyu Kim
------------------------------------
Thesis Committee Member : Hoguen Kim
------------------------------------
Thesis Committee Member : Tae Il Kim
------------------------------------
Thesis Committee Member : Seung-Yong Jeong
------------------------------------
Thesis Committee Member : Kyung Hee Chun
The Graduate School 
Yonsei University 
December 2016
ACKNOWLEDGEMENTS
The author would like to thank Yun Sun Lee for experimental work
and organizing data.
<TABLE OF CONTENTS>
ABSTRACT···········································································1
I. INTRODUCTION ··································································4
II. MATERIALS AND METHODS ·················································6
  1. Patients···········································································6
  2. Preoperative chemoradiotherapy and Surgery·······························8
  3. Quantitative real-time PCR····················································9
  4. Endoscopic findings ··························································10
  5. Assessment of tumor response to CRT and histopathology ·············10
  6. Statistical analysis ····························································12
III. RESULTS ·······································································14
   1. Patients characteristics and clinical variables ····························14
   2. mRNA expression and responses to preoperative CRT ·················17
   3. Nomogram for prediction of pCR ·········································17
IV. DISCUSSION···································································24
V. CONCLUSION ··································································35
REFERENCES ······································································37
ABSTRACT(IN KOREAN) ······················································43
LIST OF FIGURES
Figure 1. Various endoscopic findings of primary tumors after 
preoperative chemoradiotherapy. (A. no visualization; B. white scar; 
C. red scar; D. ulceration; E. remaining mass)························11
Figure 2. Nomogram to predict the probability of pathologic 
complete response (pCR) after preoperative chemoradiotherapy. 
The nomogram is used by totaling the points identified on the top 
scale for each independent six variables. The total points projected 
to the bottom scale indicate the % probability of pCR ··············21
Figure 3. Discrimination and calibration of nomogram in training set 
(n = 80). A. Receiver operating characteristic (ROC) curve by the 
multiple logistic model. Area under the ROC curve is 0.945 [ 95% 
confidence interval (CI): 0.900-0.989]. B. Calibration plot for 
probability of pCR. Predicted and actual pCR probabilities are 
plotted as logistic calibration (bootstrap 300 repetitions)···········22
Figure 4. Discrimination and calibration of nomogram in external 
validation set (n = 40). A. Receiver operating characteristic (ROC) 
curve by the multiple logistic model. Area under the ROC curve is 
0.922 [ 95% confidence interval (CI): 0.841-0.999]. B. Calibration 
plot for probability of pCR. Predicted and actual pCR probabilities 
are plotted as logistic calibration (bootstrap 300 repetitions) ······23
LIST OF TABLES 
Table 1. Patients characteristics ···········································15
Table 2. Univariate analysis of clinical variables associated with pCR 
and TRG in training set (n = 80)·········································16
Table 3. The relative quantity of biomarkers mRNA in tumor tissue 
according to ypTNM, T- and N-downstaging, TRG and pCR in 
training set (n = 80) ························································18
Table 4. Logistic regression analysis of clinical variables and 
biomarker expression in tumor tissue by RT-PCR for assessment of 
pCR in training set (n = 80) ··············································19
Table 5. Logistic regression model using biomarker expression in 
tumor tissue by RT-PCR and endoscopic finding for assessment of 
pCR in training set (n = 80) ··············································20
1ABSTRACT
Nomogram for Prediction of Pathologic Complete Remission Using 
Morphometric Change and Biomarker Expression in Rectal Cancer After 
Preoperative Chemoradiotherapy
Hyuk Hur
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Nam Kyu Kim)
Numerous molecular markers and imaging tools have been studied to predict 
pathologic complete remission (pCR) after preoperative chemoradiotherapy 
(CRT) for rectal cancer. However, none of these has not shown definite 
outcomes. The aim of this study is to develop a nomogram to predict pCR by 
analyzing relevant biomarkers and endoscopic findings. Tumor specimens 
have been collected prospectively from 120 patients before preoperative CRT
in patients with rectal cancer between November 2011 and April 2014. All 
2patients underwent curative resection with total mesorectal excision at 8 weeks 
after completeness of preoperative CRT. Using reverse transcriptase 
polymerase chain reaction (RT-PCR) analysis, mRNA expression levels of 
seven candidate biomarkers (p53, p21, Ki-67, VEGF, CD133, CD24, CD44) 
were evaluated from fresh tumor samples before CRT. The expression of 
mRNA was indicated with ΔCt by correction according to the expression of 
GAPDH (target Ct – GAPDH Ct). The relative quantity of mRNA in 
pathologic complete remission (pCR) tissue to that in non-pCR tissue was 
calculated from the relative ratios of 2-ΔCt between two conditions. Lower ΔCt 
and Higher 2-ΔCt mean higher expression of mRNA. Endoscopic evaluation has 
been done pre- and post-preoperative CRT. Clinical complete remission by 
endoscopic finding was no visualization of tumor, white scar, and red scar. 
Clinical variables were also evaluated. Univariate and multivariate logistic 
regression analysis with clinical and biologic variables were used to make a 
predictive model for pCR. Nomogram was developed in a training set (n=80)
and validated in external validation set (n=40). Both discrimination and 
calibration were measured by the area under a receiver operating characteristic 
(ROC) curve (AUC) and calibration plot, respectively. The pCR was shown in 
24 patients (30%). Among seven biomarkers, the mRNA expression levels of 
3four biomarkers (p53, p21, Ki67, CD133) significantly correlated with pCR in 
training set. Patients showing low expression of p53 and/or high expression of 
p21, Ki67, CD133 exhibited a significantly greater pCR rate. Among 27 
patients showing endoscopic clinical complete response (cCR) after 
preoperative CRT, 17 patients (63.0%) demonstrated pCR. Lower tumor 
location showed a higher pCR rate than middle tumor [19 (38.8%) vs. 
5(16.1%), p = 0.031]. By logistic regression analysis, tumor location, 
endoscopic finding after preCRT and four biomarkers (p53, p21, Ki67, CD133) 
were significantly correlated with pCR. Based on the multivariate prediction 
model with these variables, a nomogram were drawn for prediction for pCR, 
and which showed good discrimination ability in training set (AUC=0.945) 
and validation set (AUC=0.922). The calibration plot demonstrated good 
agreement between actual and predicted pCR in both patient set. The 
nomogram for prediction of pCR may be useful in treatment decisions after 
preoperative CRT to select complete responders for a wait-and-see policy or 
sphincter preserving surgery.
-----------------------------------------------------------------------------------------------
Key words : rectal cancer, chemoradiotherapy, pathologic complete remission, 
biomarkers, endoscopy, prediction nomogram.
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I. INTRODUCTION
Most of expert groups as well as treatment guideline have adopted a 
preoperative chemoradiotherapy (CRT) as preferred method to improve 
oncologic outcomes in patients with advanced middle and low rectal cancer. 
In these patients, CRT is expected to cause tumor downstaging and to allow 
performing a sphincter-saving procedure with negative circumferential
resection margin. The ideal effect of CRT is complete response when tumor is 
5totally replaced by scar. The rate of pathologic complete remission (pCR) after 
preoperative CRT varies between 12-16% in standard CRT1-3 and can increase 
up to 24-30% with advanced regimens and target chemotherapy agents.4
Patients with significant response to CRT are expected to have better 
oncologic outcomes, and those with pCR potentially might even avoid major 
surgery.5
Several biomarker models are being tested for prediction of CRT response
with conflicting results. To date a number of tumor proteins are being studied 
as candidate predictive markers that can be used to predict response to CRT in 
rectal cancer. These proteins are involved in carcinogenesis in different ways –
apoptosis, tumor proliferation, angiogenesis, mismatch repair and their 
expression can easily be assessed by immunohystochemical (IHC) analysis or 
reverse transcriptase polymerase chain reaction (RT-PCR). Previously we 
described a scoring system based on IHC analysis of four tumor proteins (p53, 
VEGF, p21 and Ki67) that accurately predicted pCR in middle and low rectal 
cancer.6 However IHC lacks of reproducibility and quantitative assessment of 
gene expression.
Gross tumor characteristics detected by endoscopy have been suggested for 
assessment of tumor response after preoperative CRT. It was suggested that 
6regularly scheduled reassessments might provide a safe alternative to patients 
with endoscopic findings of clinical complete response.
Each predictive modality has its own strength and weakness; therefore, there 
have been several attempts to develop models or nomograms to predict the 
treatment response of preoperative CRT. A combination of two or more 
modalities provided complementary information about treatment response and 
yielded higher accuracy and specificity than the individual investigations. The 
combination of morphological and functional imaging with the numerous 
potential molecular markers and identified genes will provide comprehensive 
information on each individual patient and make possible individualized 
treatment therapy.
The aim of this study was to develop a prediction nomogram of pCR to 
preoperative CRT in rectal cancer based on mRNA expression of tumor 
proteins measured by RT-PCR and endoscopic findings.
II. MATERIALS AND METHODS
1. Patients
Total 120 consecutive patients with rectal cancer were enrolled prospectively 
7between November 2011 and April 2014. Following inclusion criteria were 
used: histologically proven primary rectal adenocarcinoma, clinically staged as 
T2N(+)M0 or T3-4NanyM0 planned for preoperative CRT and curative resection.
Eighty patients were assigned to the training set for development of the 
nomogram for prediction of pCR. For external validation of the nomogram, 40 
patients assigned to the validation set in sequence of treatment time.
All the patients underwent preoperative staging (clinical T- and N-staging) 
with the use of magnetic resonance imaging (MRI) reviewed by single 
radiologist and endorectal ultrasound (EUS) performed by a single surgeon. 
MRI can evaluate circumferential margin and pelvic lymph node status more 
accurately. So, in case of discrepancies in T- or N-staging between MRI and 
EUS, we used MRI for clinical staging. Clinical N(+) stage was stated if 
regional lymph nodes were found to be larger than 10 mm or had spiculated 
shape. 
After inclusion and before starting preoperative CRT all patients underwent 
rigid sigmoidoscopy and two-punch biopsy from visibly the deepest area of 
tumor, which was further used for reverse transcriptase polymerase chain 
reaction (RT-PCR) analysis. Low rectal cancer was stated if lower tumor edge 
was located < 5 cm from the anal verge by rigid sigmoidoscopy, and middle 
8rectal cancer if it was at 5-10 cm from the anal verge.
Endoscopy was performed before preoperative CRT and 4 weeks after 
completion of preoperative CRT. We defined the endoscopic findings of tumor 
after preoperative CRT and evaluated treatment response. 
The study was approved by the Institutional Review Board (IRB) for the 
protection of human subjects at the Severance Hospital, Yonsei University 
College of Medicine.
2. Preoperative chemoradiotherapy and Surgery
All the patients received preoperative CRT as indicated by the 
multidisciplinary team decision. Radiation therapy was delivered using dual-
photon linear accelerators at an energy level of 6-MV/10-MV. Long-course 
radiation therapy included 25 fractions 1.8Gy each delivered to the pelvis over 
a period of 5 weeks (5 days per week), resulting in 45Gy total radiation dose 
that was followed by the 5.4 Gy boost targeting the primary tumor.
Chemotherapy was administered to all patients with two types of regimen
options, 5-fluorouracil with leucovorin or xeloda only. Two cycles of 
intravenous bolus injection of 5-fluorouracil (425 mg/m2/day) and leucovorin 
(20 mg/m2/day) were administered for 5 days during the first and fifth weeks 
9of radiation therapy. Xeloda was continuously administered orally at a dose of 
1450 mg/m2/d twice daily during the radiation therapy period.
All the patients completed the preoperative CRT in full and underwent 
curative surgery at 8 weeks after completion of CRT.
3. Quantitative real-time PCR
Total RNA was isolated from fresh samples and used for RT-PCR. We 
extracted total RNA with an RNeasy plus mini kit (Qiagen, Valencia, CA, 
USA) according to the manufacturer’s instructions. We synthesized cDNA 
using a Transcriptor first strand cDNA synthesis kit (TaKaRa Bio Inc., Otsu, 
Japan) and 1 μg of total RNA. We conducted real-time polymerase chain 
reaction (PCR) in duplicate using TaqMan master mix (Applied Biosystems, 
Foster City, CA, USA) and the Applied Biosystems viia7 Real-Time PCR 
System. Seven biomarkers (P53, P21, Ki67, VEGF, CD133, CD24, CD44) 
were chosen as candidates from our previous research findings6 and published 
data, and mRNA expression levels were investigated. We normalized the 
mRNA expression levels of TP53 (assay ID Hs01034249_m1), CDKN1A 
(assay ID Hs00355782_m1), MKI67 (assay ID Hs01032443_m1), VEGFA 
(assay ID Hs00900055_m1), PROM1 (assay ID Hs01009250_m1), CD44 
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(assay ID Hs01075861_m1) and CD24 (assay ID Hs03044178_g1 to that of 
the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (assay ID 
Hs02758991_g1) housekeeping gene. We performed relative quantification 
using the QuantStudio software v1.2 (Applied Biosystems). Expression level 
of each protein was measured as ΔCt and 2−ΔCt compared to expression of 
GAPDH (ΔCt = target Ct – GAPDH Ct). Lower ΔCt and higher 2−ΔCt means 
the higher expression of each protein.
4. Endoscopic findings
We ventured a hypothesis that no visualization of tumor, white scar, or red 
scar would be associated with “cCR” and ulcerations and remaining masses of 
any size would be associated with "non-cCR” (Figure 1). The endoscopic 
findings were interpreted by two independent endoscopists blinded to the 
patients’ clinical information. The consistency of the endoscopic findings 
between the two independent observers was greater than 90%. In cases of 
disagreement, the endoscopic finding was determined by consensus.
5. Assessment of tumor response to CRT and histopathology
All of the operation specimens were reviewed by a single pathologist that
11
Figure 1. Various endoscopic findings of primary tumors after preoperative chemoradiotherapy. 
(A. no visualization; B. white scar; C. red scar; D. ulceration; E. remaining mass).
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was blinded to patient clinical information. Staging was performed according 
to the 7th American Joint Committee on Cancer (AJCC) TNM staging manual. 
T-downstaging was observed if pathologic T-stage (pT) was smaller compared 
to clinical T-stage (cT) in the same patient. In patients who initially presented 
with clinically positive lymph nodes [cN(+)], N-downstaging was defined as 
conversion to pathological lymph node negative status [pN(-)].
The tumor response to preoperative CRT was evaluated using the Mandard’s 
tumor regression grade (TRG). Tumors classified as TRG1 or TRG2 were 
considered to be responders, whereas tumors staged as TRG3-5 were defined 
as nonresponders. Pathologic complete remission (pCR) was stated if no 
viable tumor was found (TRG1) with no lymph node involvement (pN0).
6. Statistical analysis
We built the nomogram using logistic regression model to discriminate 
between pCR and non-pCR in training set (n = 80). After development of the 
nomogram, validation set (n = 40) was used for validity verification in external 
patients cohort.
Categorical data were analyzed using Fisher’s exact or χ2 tests. Continous 
variables were analyzed using two-sided t-test or Mann-Whitney test.
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Univariate logistic regression analysis were used first to assess the association 
between each variable and pCR and to select variables, which entered 
following multivariate logistic regression analysis. The final multivariate 
model was chosen on the basis for the pCR prediction model and tested by 
Hosmer-Lemeshow goodness of fit test for evaluation of prediction ability. 
Based on the prediction model with identified predictive factors, a nomogram
were drawn for prediction of pCR. The model performance was quantified in 
terms of the discrimination and calibration performance. Discrimination is the 
predictor’s ability to separate patients between pCR and non-pCR. 
Discrimination ability was meseared by the area under a receiver operating 
characteristic (ROC) curve. A higher ROC area under the curve (AUC) 
indicates a better discriminatory power. An AUC of 0.50 indicates that the test 
is good as random chance for discriminating an outcome, whereas an AUC of 
1.0 indicates perfect discrimination of the rest (sensitivity and specificity of 
100%). In general, the model is considered relatively good for values above 
0.75. Calibration is the agreement between actual probability and predicted 
probability of pCR produced by the model. This was evaluated with a 
calibration curve, where patients were grouped by predicted pCR and then 
plotted as actual versus predicted pCR. We used the bootstrapping resampling 
14
method (300 repetitions) to obtain relatively unbiased estimates and to check 
internal validation. Both discrimination and calibration were evaluated in the
training and the validation set, respectively. All statistical analyses were 
performed using SPSS software version 20 (SPSS, Chicago, IL, USA) and R 
software version 3.0.1 (the R foundation for statistical computing, Vienna, 
Austria). Values of p<0.05 were considered statistically significant.
III. RESULTS
1. Patients characteristics and clinical variables
A total of 120 consecutive patients were included in this trial. Detailed 
patient characteristics in training and validation set are listed in Table 1. 
Before starting treatment, the majority of patients in training set presented 
with advanced T-stage and N-stage: cT3-T4 stage was diagnosed in 97.5% and 
cN(+) – in 81.2% of patients (Table 1). 
In training set, pathologically confirmed tumor downstaging after 
preoperative CRT was found in 60.0% (48/80) of patients for T-stage and in 
57.5% (46/68) of patients for N-stage. Good response to preoperative CRT 
(TRG1 and TRG2) was observed in 40.0% of patients, and pCR was revealed 
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Table 1. Patient characteristics
Characteristics Training (n=80) Validation (n=40) p
Median age, years (range) 60 (36-86) 64 (37-86) 0.497
Sex 0.791
  Male 50 (62.5) 24 (60.0)
  Female 30 (37.5) 16 (40.0)
Median distance from AV, cm (range) 5.3 (1-11) 5.3 (1-10) 0.923
Tumor location 0.895
  Middle 31 (38.8) 16 (40.0)
  Low 49 (61.3) 24 (60.0)
Median Pre CRT CEA, ng/mL (range) 8.28 (0.5-51.8) 8.13 (0.9-46.2) 0.944
Initial tumor differentiation 0.576
  G1/G2 13 (16.3)/60 (75.0) 4 (10.0)/31 (77.5)
  G3/G4 6 (7.5)/1 (1.3) 5 (12.5)/0 (0.0)
Clinical T and N stage 0.846
  cT2N+ 2 (2.5) 1 (2.5)
  cT3N-/N+ 14 (17.5)/54 (67.5) 10 (25.0)/25 (62.5)
  cT4N-/N+ 1 (1.2)/9 (11.2) 0 (0.0)/4 (10.0)
Endoscopy 0.781
  cCR 26 (32.5) 12 (30.0)
  non-cCR 54 (67.5) 28 (70.0)
Pathological T and N stage 0.960
  ypT0N- 24 (30.0) 11 (27.5)
  ypT1N-/N+ 6 (7.5)/1 (1.2) 2 (5.0)/0 (0.0)
  ypT2N-/N+ 12 (15.0)/3 (3.8) 8 (20.0)/1 (2.5)
  ypT3N-/N+ 16 (20.0)/16 (20.0) 7 (17.5)/9 (22.5)
  ypT4N+ 2 (2.5) 2 (5.0)
TRG 0.987
  TRG1/TRG2 24 (30.0)/16 (20.0) 11 (27.5)/9 (22.5)
  TRG3/TRG4 28 (35.0)/12 (15.0) 14 (35.0)/6 (15.0)
Operation 0.955
  Low anterior resection 56 (70.0) 29 (72.5)
  uLAR with CAA 20 (25.0) 9 (22.5)
  APR 4 (5.0) 2 (5.0)
AV, anal verge; CEA, carcinoembryonic antigen; G1, well differentiated; G2, moderately 
differentiated; G3, poorly differentiated; G4, undifferentiated; cCR, clinical complete response; 
TRG, tumor regression grade; uLAR, ultra low anterior resection; CAA, coloanal anastomosis. 
Unless indicated otherwise, numbers in parenthesis are percentages.
in 30.0% of patients. The clinical and pathologic characteristics of patients in
validation set are similar with training set (Table 1).
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Table 2. Univariate analysis of clinical variables associated with pCR and TRG in training set (n = 80).
Characteristics
pCR
p
TRG
p
Yes (n=24) No (n=56)
TRG1-2
(n=40)
TRG3-4
(n=40)
Age ≤60 14 (33.3) 28 (66.7)
0.494
18 (42.9) (57.1)
0.179
>60 10 (26.3) 28 (73.7) 22 (57.9) 16 (42.1)
Sex Male 13 (26.0) 37 (74.0)
0.313
25 (50.0) 20 (50.0)
1.000
Female 11 (36.7) 19 (63.3) 15 (50.0) 15 (50.0)
Tumor location (cm)
Low (1-5) 19 (38.8) 30 (61.2)
0.031
29 (59.2) 20 (40.8)
0.039
Middle (>5) 5 (16.1) 26 (83.9) 11 (35.5) 20 (64.5)
Pre CRT CEA
(ng/mL)
≤5 17 (34.7) 32 (65.3)
0.249
27 (55.1) 22 (44.9)
0.251
>5 7 (22.6) 24 (77.4) 13 (41.9) 18 (58.1)
Clinical T stage       cT2/cT3 20 (28.6) 50 (71.4)
0.477
33 (47.1) 37 (52.9)
0.176
cT4 4 (40.0) 6 (60.0) 7 (70.0) 3 (30.0)
Clinical N stage            cN(-) 6 (40.0) 9 (60.0)
0.363
8 (53.3) 7 (46.7)
0.775
cN(+) 18 (27.7) 47 (72.3) 32 (49.2) 33 (50.8)
Histology G1/G2 22 (30.1) 51 (69.9)
1.000
37 (50.7) 36 (49.3)
1.000
G3/G4 2 (28.6) 5 (71.4) 3 (42.9) 4 (57.1)
Endoscopy cCR 18 (69.2) 8 (30.8) <0.001 23 (88.5) 3 (11.5) <0.001
non-cCR 6 (11.1) 48 (88.9) 17 (31.5) 37 (68.5)
pCR, pathologic complete response; TRG, tumor regression grade; CEA, carcinoembryonic antigen; G1, 
well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated; cCR, 
clinical complete response. Unless indicated otherwise, numbers in parenthesis are percentages.
Univariate analysis of different clinical variables in training set revealed that
tumor location in lower rectum was significantly associated with pCR and 
TRG response. Tumors located in lower rectum demonstrated significantly 
higher rate of pCR (38.8%, 19/49) and TRG1-2 (59.2%, 29/49) than middle
rectal tumors (16.1%, 5/31 and 35.5%, 11/31, p=0.03 and 0.039, respectively). 
Endoscopic findings demonstrated a significant correlation between clinical 
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CR and pCR or TRG1-2 (Table 2).
2. mRNA expression and responses to preoperative CRT
In training set, the level of expression value of the studied biomarkers mRNA 
was not significantly different between patients who did and did not develop 
T- or N-downstaging. But mRNAs of four biomarkers (p53, p21, Ki-67 and 
CD133) were expressed differently between patients who had a pCR and those 
who had not develop a pCR, as well as between responders to CRT (TRG 1-2) 
and non-responders (TRG 3-4). Responders to CRT and patients with a pCR 
demonstrated significantly higher ΔCt and lower 2−ΔCt of p53 mRNA, but 
lower ΔCt and higher 2−ΔCt of mRNA of p21, Ki-67 and CD133 (Table 3).
3. Nomogram for prediction of pCR
In univariate and multivariate logistic regression analysis in training set, 
tumor location, endoscopic finding, low expression of p53 mRNA and high 
expression of p21, Ki67, CD133 mRNA was significantly associated with pCR 
(Table 4). These variables were selected for further analysis as possible 
predictors of pCR to CRT.
Prediction models for pCR using logistic regression analysis were suggested 
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Table 3. The relative quantity of biomarkers mRNA in tumor tissue according to ypTNM, T- and N-downstaging, TRG and pCR in trainage set (n = 80).
Biomarker Expression value
ypTNM T-downstaging N-downstaging TRG pCR
Stage 0, I 
(n=42)
Stage II,III 
(n=38)
p
Yes 
(n=48)
No 
(n=32)
p
Yes 
(n=46)
No 
(n=22)
p
TRG1-2 
(n=40)
TRG3-4 
(n=40)
p
Yes 
(n=24)
No 
(n=56)
p
p53
ΔCt (mean±SD) 6.35±1.54 6.00±1.15 0.266 6.39±1.83 6.07±2.42 0.511 6.45±1.91 5.60±2.47 0.122 6.65±1.81 5.87±2.28 0.042 6.97±1.95 5.96±2.08 0.047
2-ΔCt (mean±SD) 1.74±1.51 1.84±1.24 0.720 2.78±2.68 7.27±4.76 0.213 2.91±2.86 10.04±6.2 0.159 1.52±1.16 7.64±0.97 0.038 1.31±1.03 5.98±1.20 0.036
p21
ΔCt (mean±SD) 6.09±1.71 6.31±1.06 0.493 6.04±1.63 6.31±1.19 0.413 6.16±1.36 6.28±1.36 0.732 5.98±1.64 6.31±1.27 0.048 5.58±1.71 6.39±1.30 0.045
2-ΔCt (mean±SD) 1.48±1.99 0.82±0.52 0.053 1.49±1.04 0.89±0.72 0.069 1.25±0.88 0.97±0.80 0.506 1.57±0.19 0.93±0.08 0.039 2.13±2.67 0.87±0.72 0.033
Ki67
ΔCt (mean±SD) 8.91±3.19 10.01±3.98 0.175 9.48±3.73 9.63±3.98 0.856 9.55±4.25 9.48±3.70 0.950 8.62±3.38 10.46±4.0 0.043 8.16±2.77 10.13±4.05 0.033
2-ΔCt (mean±SD) 1.35±1.37 0.86±0.90 0.056 3.41±2.12 1.41±0.55 0.489 3.74±2.49 1.38±0.38 0.509 4.54±0.67 0.69±0.05 0.006 6.05±2.71 1.14±2.05 0.002
VEGF
ΔCt (mean±SD) 5.91±1.86 6.19±2.01 0.521 6.00±1.83 6.09±2.10 0.840 6.22±1.89 5.65±2.01 0.259 5.71±1.87 6.37±1.95 0.130 5.68±1.82 6.19±1.97 0.272
2-ΔCt (mean±SD) 2.78±4.93 2.36±3.91 0.680 2.55±1.64 2.63±1.20 0.932 2.22±1.18 3.17±1.73 0.406 3.03±0.91 2.14±0.94 0.374 3.22±0.72 2.31±0.80 0.403
CD133
ΔCt (mean±SD) 8.52±2.15 9.03±1.68 0.246 8.73±2.35 9.13±2.07 0.440 8.98±2.33 8.92±2.27 0.919 8.36±2.05 9.42±2.32 0.034 8.13±2.26 9.22±2.17 0.046
2-ΔCt (mean±SD) 1.71±1.66 1.09±1.30 0.066 2.22±1.98 1.50±1.40 0.358 1.85±0.51 1.89±0.81 0.958 2.50±0.27 1.37±0.26 0.045 3.28±0.30 1.35±0.03 0.036
CD24
ΔCt (mean±SD) 3.97±1.26 3.87±1.30 0.740 4.01±1.21 3.79±1.37 0.452 3.89±1.18 3.81±1.54 0.829 3.90±1.18 3.94±1.37 0.899 3.91±1.21 3.92±1.31 0.973
2-ΔCt (mean±SD) 1.65±1.67 1.77±1.72 0.748 1.57±0.59 1.92±0.83 0.368 1.67±0.61 2.06±0.07 0.401 1.68±0.67 1.73±0.71 0.890 1.72±0.90 1.70±0.59 0.959
CD44
ΔCt (mean±SD) 4.89±1.74 4.90±1.01 0.986 4.93±1.63 4.84±1.08 0.795 4.82±1.16 4.71±1.07 0.726 4.81±1.73 4.98±1.06 0.613 5.00±2.09 4.85±1.05 0.659
2-ΔCt (mean±SD) 1.13±0.72 1.00±0.72 0.425 1.08±0.69 1.06±0.76 0.934 1.09±0.71 1.16±0.85 0.699 1.18±0.72 0.96±0.70 0.181 1.14±0.71 1.04±0.72 0.605
TRG, tumor regression grade; pCR, pathologic complete remission.
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Table 4. Logistic regression analysis of clinical variables and biomarker expression in tumor 
tissue by RT-PCR for assessment of pCR in training set (n = 80).
variable
univariable multivariable
OR 95% CI p OR 95% CI p
Age 0.993 (0.953, 1.034) 0.722
Gender 1.648 (0.621, 4.369) 0.315
BMI (kg/m2) 1.003 (0.862, 1.167) 0.967
AV_distance 0.807 (0.641, 1.017) 0.070
Tumor_location (cm) 0.304 (0.099, 0.927) 0.036 0.086 (0.005, 1.491) 0.042
Pre_CRT_CEA (ng/mL) 0.995 (0.950, 1.041) 0.816
Clinical_Tstage 0.388 (0.023, 6.518) 0.511
Clinical_Nstage 0.574 (0.179, 1.846) 0.352
Histology_grade 1.545 (0.381, 6.265) 0.543
Endoscopic_finding 18.00 (5.481,59.112) 0.000 134.676 (7.616,2381.642) 0.001
p53 ΔCt 1.713 (1.148, 2.556) 0.008 2.19 (0.775, 6.189) 0.039
p53 2-ΔCt 0.55 (0.331, 0.914) 0.021 0.972 (0.207, 4.556) 0.071
p21 ΔCt 0.598 (0.404, 0.885) 0.010 0.769 (0.207, 2.855) 0.095
p21 2-ΔCt 2.281 (1.281, 4.062) 0.005 3.75 (0.497, 28.277) 0.020
Ki67 ΔCt 0.655 (0.480, 0.894) 0.008 0.384 (0.126, 1.169) 0.042
Ki67 2-ΔCt 1.922 (1.247, 2.961) 0.003 0.395 (0.086, 1.805) 0.023
VEGF ΔCt 0.868 (0.675, 1.116) 0.270
VEGF 2-ΔCt 1.044 (0.943, 1.155) 0.406
CD133 ΔCt 0.627 (0.447, 0.880) 0.007 1.289 (0.401, 4.147) 0.040
CD133 2-ΔCt 1.637 (1.177, 2.278) 0.003 3.283 (0.998, 10.796) 0.035
CD24 ΔCt 0.993 (0.680, 1.451) 0.972
CD24 2-ΔCt 1.008 (0.758, 1.339) 0.959
CD44 ΔCt 1.076 (0.779, 1.488) 0.656
CD44 2-ΔCt 1.194 (0.616, 2.312) 0.600
BMI, body mass index; AV, anal verge.
with these six clinical and biological variables (Table 5). Of three prediction 
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Table 5. Logistic regression model using biomarker expression in tumor tissue by RT-PCR and 
endoscopic finding for assessment of pCR in training set (n = 80).
Model 1
Varaible OR lower upper p
p53deltaCT 1.948 1.212 3.547 0.013
p21deltaCT 0.537 0.312 0.848 0.014
Ki67deltaCT 0.671 0.434 0.905 0.034
CD133deltaCT 0.799 0.51 1.197 0.296
AUC 0.859375
Model 2
Variable OR lower upper p
p53deltaCT 2.101 1.186 3.722 0.011
p21deltaCT 0.518 0.307 0.874 0.014
Ki67deltaCT 0.726 0.512 1.03 0.073
CD133deltaCT 0.787 0.515 1.202 0.268
Tumor location 0.314 0.074 1.337 0.117
AUC 0.875744
Model 3
Variable OR lower upper p
p53deltaCT 1.717 1.039 3.263 0.053
p21deltaCT 0.439 0.193 0.799 0.019
Ki67deltaCT 0.642 0.384 0.9 0.027
CD133deltaCT 0.594 0.318 1.002 0.069
Endoscopic 39.228 6.989 399.305 <.0001
Tumor location 0.356 0.047 2.063 0.271
AUC 0.9449405
models according to the including variables, model 3 with all six variables
demonstrated the highest AUC and was chosen. The Hosmer-Lemeshow 
goodness of fit test was not significant (p = 0.984), indicating good fit of this
model. This prediction model was visually represented by a nomogram to
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Figure 2. Nomogram predicting the probability of pathologic complete remission (pCR) after 
preoperative chemoradiotherapy in rectal cancer. The nomogram is used by totaling the points 
identified on the top scale for each independent six variables. The total points projected to the 
bottom scale indicate the % probability of pCR.
predict the probability of pCR (Figure 2). To use the nomogram, a vertical line 
is drawn up to the top point row to assign points for each variable. Then the 
total number of points is calculated, and a vertical line is drawn 
downwardsfrom the total point row to obtain the probability of pCR. 
According to nomogram, patients with 210, 240, 270 total points had 
estimated pCR probability of 10, 50, 90 %, respectively. Figure 3 demonstrates 
ROC curve and calibration plot of training set. Area under the ROC curve of
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Figure 3. Discrimination and calibration of nomogram in training set (n = 80). A. Receiver 
operating characteristic (ROC) curve by the multiple logistic model. Area under the ROC 
curve is 0.945 [ 95% confidence interval (CI): 0.900-0.989]. B. Calibration plot for probability 
of pCR. Predicted and actual pCR probabilities are plotted as logistic calibration (bootstrap 
300 repetitions).
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Figure 4. Discrimination and calibration of nomogram in external validation set (n = 40). A. 
Receiver operating characteristic (ROC) curve by the multiple logistic model. Area under the 
ROC curve is 0.922 [ 95% confidence interval (CI): 0.841-0.999]. B. Calibration plot for 
probability of pCR. Predicted and actual pCR probabilities are plotted as logistic calibration 
(bootstrap 300 repetitions).
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the multivariate model was 0.945 [95% confidence interval (CI): 0.900–0.989]. 
The calibration plot showed good agreement between predicted and actual 
probability. In the external validation set, the AUC was 0.922 [95% confidence
interval (CI): 0.841–0.999]. The calibration plot of predicted and actual 
probability showed good correlation in low and high probability area.
However, in middle probability area, it seems not to show a good correlation, 
because the intermediate probability could be ambiguous for binary variable 
(Figure 4).
IV. DISCUSSION
Various modalities have been studied and proposed to assess and predict 
responses to CRT. For morphologic assessment of tumor response after 
preoperative CRT, endoscopic findings and imaging studies, including 
magnetic resonance imaging (MRI) and positron emission tomography (PET), 
have been used and demonstrate good results. Clinical factors and serum 
carcinoembryonic antigen (CEA) have also been investigated and shown to 
hold some predictive value. Notwithstanding, due to the limitations of these 
modalities, many molecular markers have been assessed for evaluation and 
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prediction of tumor response to preoperative CRT in patients with rectal cancer. 
More than 40 different biomarkers have been explored in the literature, with 
conflicting results in predicting the outcomes of CRT. Molecular biomarkers 
analyzed using immunohistochemistry and gene expression profiling have 
been investigated and may play a possible role as predictive models for 
tailored treatment of patients undergoing preoperative CRT.
In the present study, we developed the nomogram combining endoscopic 
findings of morphometric tumor change and mRNA expression levels of four 
biomarkers (p53, p21, Ki67 and CD133) by quantitative RT-PCR to predict 
pCR in rectal cancer patients receiving preoperative CRT. These predictive 
model were externally validated and showed a good model performance in 
terms of calibration and discrimination. We believe that this comprehensive 
nomogram is useful for pCR prediction and would be the guidance for 
individualized treatment.
Unlike other works in this field that evaluated prognostic value of biomarkers 
in rectal cancer, in this study we developed a prediction system that is based 
on evaluation of mRNA expression of 4 biomarkers and endoscopic finding in 
a complex. This prediction model can be utilized after completion of CRT in 
rectal cancer patients to predict a pCR. Previously we reported on a prognostic 
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scoring system that utilized the level of expression of p53, VEGF, p21 and 
Ki67 measured by IHC analysis.6 These proteins were chosen from a panel of 
12 markers as having a significant correlation between their expression level 
and pCR in 81 patients. One of the major limits of that study was 
implementing IHC analysis to evaluate protein expression in tumor samples.
Although this technique is wide-spread and easily available, still its major 
disadvantage is low reproducibility. Hence for present study we employed 
real-time RT-PCR as a more reliable, sensible and reproducible method that 
allows quantification of gene expression.7 Although the number of studied 
patients is rather small, one of the strengths of this study is its prospective 
nature. In contrast to our previous study all consecutive patients in the study 
period were included thus overcoming the influence of selection bias inherent 
in retrospective studies. In addition, we added the endoscopic finding as 
clinical tool for evaluation of morphometric changes of tumor after 
preoperative CRT. Gross tumor response findings would be the valuable 
assessment modality for prediction of pathologic tumor response. In our study, 
we could demonstrate the importance of endoscopic evaluation of primary 
tumor after preoperative CRT for rectal cancer.
Still, the observed pCR rate (30%) is higher than reported by most groups 
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worldwide. This partly can be related to a higher proportion of patients with 
tumors below 5 cm from anal verge (61.3%). Among studied clinical factors 
tumor location in low rectum was found to be the only significant predictor of 
good response to CRT and pCR in the present research. It is difficult to rule 
out any evident reasons for this phenomenon. One of the possible theoretical 
explanations to higher sensitivity to CRT of low rectal tumors compared to 
middle rectal tumors is that they might be better vascularized and faster 
growing. The quicker cell cycle may influence the sensitivity and response rate 
to CRT. The second possible explanation is that low rectal tumors can be 
biologically different from higher ones, thus it can be reflected in differences
in biomarkers profile between them. We are not aware of any evidence-based 
data that can support or refute this idea. But if this result is not accidental this 
may open a way to further research in the field of finding biologic differences 
between low and high rectal tumors.
Another possible limitation of this study is that the samples were collected 
and analyzed only before starting CRT. We didn’t study tumor samples after 
completion of CRT or after surgery, so we didn’t evaluate possible changes in 
biomarkers mRNA expression that could be induced by CRT. However, the 
major aim of this study is to predict pCR after CRT and provide the useful 
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information in making treatment strategies after CRT. The developed 
predictive model is based on RT-PCR analysis of a group of biomarkers 
analyzed together but not independently. This may help to get a more realistic 
profile of the tumor and better predict its response to CRT.
The selection of p53, VEGF, p21 and Ki67 as candidate biomarkers for the 
present study was based on our previous research findings6 and published data 
that supports the correlation between expression of these proteins and rectal 
cancer sensitivity to CRT. 
Among abovementioned tumor proteins p53 is probably the most extensively 
studied biomarker in this field. Protein p53 plays an important role in genetic 
stability, cell proliferation, apoptosis and inhibition of angiogenesis, and in a 
number of studies the presence of p53 mutations was found to correlate 
inversely with pCR, although not in all of them this association was 
significant.6,8-22 Twelve of these studies9-18 used IHC staining to identify 
mutant p53 and only in two of them, including our previous research6,16 a 
significant correlation was demonstrated between strong mutant p53 staining 
in pretreatment tumor biopsies and resistance to CRT. The group of Spitz et 
al.16 was able to show that lack of p53 staining is strongly correlated with 
response to CRT (p=0.02) and strong p53 staining is related to residual cancer 
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in regional lymph nodes (p=0.02). Other 4 studies utilized RT-PCR to measure 
the expression of this biomarker,19-22 and three of them,8,20,21 like our present 
study, demonstrated lower prevalence of p53 mutation in patients with pCR. 
Among them only the group of Rebischung et al.21 revealed a significant 
correlation between low expression of p53 and pCR. The results of our present 
investigation confirm the findings from our previous research6 and other 
research groups16,21 that low expression of mutant p53 is predictive of tumor 
response to CRT and a pCR. 
Another biomarker for apoptosis is p21 that can inhibit cell cycle through 
p53-dependent and p53-independent pathways, so presumably tumor cells 
expressing p21 would be more prone to chemotherapy agents and radiation. Its 
clinical significance in rectal cancer is still not well described as controversial 
data is reported to date. Earlier reports9,10 failed to confirm association 
between expression of p21 and prognosis whereas later reasearch17,23
demonstrated this link. Our present work is consistent with our previous IHC 
study6 and showed that high expression of p21 is strongly associated with pCR. 
Conversely in the paper of Sim et al. high IHC staining of p21 in tumors 
before starting and after 7 days of CRT was significantly correlated with non-
pCR and decreased disease free survival. 
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One of the biomarkers of high proliferating activity of tumor cells is Ki67. 
Earlier its higher expression on IHC analysis was found to be correlated with 
response to radiation only,24 but not to CRT25 in rectal cancer. The findings of 
our present work and previous study6 demonstrate significant correlation 
between high expression of Ki67 and pCR. This suggests that proliferating 
tumors may be more sensible to a long course CRT. 
Besides abovementioned four biomarkers we added to the initial panel three 
cancer stem cell proteins (CD133, CD24, CD44) that are most often described 
as having prognostic value in colorectal cancer. Cancer stem cell has the 
characteristics of resistance to chemotherapy and radiotherapy. Therefore, 
there have been some efforts to investigate the correlation of cancer stem cell 
markers with the treatment response to CRT. CD133 is probably the most 
studied marker of colorectal cancer stem cells. A number of research groups26-
31 reported correlation between CD133 expression and clinicopathologic 
features and oncologic outcomes in rectal cancer patients, while others 
couldn’t demonstrate this association.32 CD133 expression means the 
existence of cancer stem cell and high level is correlated with resistance to 
CRT. In contrast, high expression of CD133 mRNA demonstrated better 
response to CRT and higher pCR rate in our study. The level of CD24 was also 
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found to be significantly associated with CRT response in some reports. Huh et 
al. revealed that, among 13 molecular markers, only elevated CD44 mRNA 
level in pretreatment biopsies was predictive of poor tumor regression, and 
CD133 level had no significant correlation with CRT response. Until now, 
there is no confirmative result that cancer stem cell marker is predictive of 
CRT response and useful in clinical field. More investigation is needed to 
develop predictive model using cancer stem cell markers.
Habr-Gama et al. attempted to provide a clear definition of complete clinical 
response (cCR) after preoperative CRT using endoscopic features9. They 
defined the positive and negative signs for cCR. Positive signs for cCR 
frequently included whitening of the mucosa, presence of any telangiectasia, 
subtle loss of pliability of the rectal wall harboring the scar, and no gross 
evidence of residual tumor. In contrast, positive signs of residual disease 
included residual deep ulceration, superficial ulcer irregularity, palpable 
nodule, and significant stenosis. 
We ventured a hypothesis that no visualization of tumor, white scar, or red 
scar would be associated with “cCR” and ulcerations and remaining masses of 
any size would be associated with "non-cCR.” Of the 26 patients that 
demonstrated endoscopic cCR, 18 (69.2%) showed pCR. Of the 54 patients 
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that demonstrated endoscopic non-cCR, 48 (88.9%) showed non-pCR. For 
assessment of pathologic complete responses, endoscopic findings exhibited
75.0% sensitivity and 85.7% specificity. Endoscopic findings were 
significantly correlated with tumor response after preoperative CRT for rectal 
cancer. 
To date, there have been several attempts to develop models or nomograms to 
predict the outcomes of CRT. Van stiphout et al. suggested a nomogram
predicting pCR for locally advanced rectal cancer based on clinical features 
and early sequential 18F-FDG PETCT imaging. The pCR rates were 21.4% in 
training set (n = 112) and 23.1% in validation set (n = 78). The selected 
predictive features for pCR were cT-stage, cN-stage, response index of 
SUVmean and maximal tumor diameter during treatment. The model
performances (AUC) were 0.78 (training) and 0.70 (validation). The high 
probability group for pCR resulted in 100% correct predictions for training 
and 67% for validation. 
Jwa et al. assessed a nomogram to predict ypN status after preoperative CRT 
in rectal cancer. The nomogram was developed in a training cohort (n = 891) 
using logistic regression analyses and was validated in a separate cohort (n = 
258). Patient age, preoperative CRT tumor differentiation, cN stage, ypT stage, 
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lymphovascular invasion, and perineural invasion were reliable predictors of 
LN metastasis after preoperative CRT and were used for the construction of 
the nomogram. The nomogram showed good discrimination ability in training 
and validation cohort. The calibration plot suggested good agreement between 
actual and predicted LN status after preoperative CRT.
In present study, prediction model consisting of tumor location, endoscopic 
finding, and four biomarkers expression demonstrated a highly value to 
discriminate between pCR and non pCR. We produced a nomogram for 
prediction of pCR using six variables and could be valuable system in clinical 
field.
Comparing to IHC the RT-PCR approach is less time consuming and more 
reliable and endoscopic morphometric change can be easily accessible. The 
prediction model demonstrated high discrimination and calibration abilities in 
identifying patients who are prone to develop a pCR and thus to have a better 
outcome and possibly to avoid major surgery. But before implementing this 
prediction model to practice it should be tested and validated on other large 
independent patient cohort. This process is planned as the next step in our 
work.
Our prediction nomogram demonstrated good performance of discrimination 
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and calibration abilities in training set. However, despite good discrimination 
ability in validation set, calibration plot did not perfectly show good agreement.
The calibration plot showed good correlation in low and high probability of 
pCR but not in middle probability area. This prediction nomogram may be 
useful in patients with low or high probability, but for the patients with 
intermediate scores, we need more reliable and substantial prediction model.
As shown in our study, a combination of clinical and biologic variables
provided complementary information about treatment response and yielded 
higher accuracy and specificity than the individual investigations. The 
combination of morphological imaging and the numerous potential molecular 
markers will provide comprehensive information on each individual patient 
and make possible individualized treatment therapy. The prediction of 
complete tumor remission has been regarded as important, because it impacts 
clinical decisions for treatment strategy. If complete remission of rectal cancer 
after preoperative CRT can be predicted, radical surgery which results in 
increasing postoperative morbidity and poor quality of life with stoma can be 
avoided. In addition, local excision or wait-and-see treatment strategies can be 
recommended if the tumor shows an excellent tumor response to preoperative 
CRT for rectal cancer. 
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There are still controversies regarding outcomes of predictive modalities of 
treatment response after preoperative CRT in rectal cancer. Combined models 
may be the future trend for predicting treatment responses. The ability to 
predict pathological tumor response before treatment will significantly impact 
patient selection for preoperative CRT and can potentially modify treatment 
strategies.
V. CONCLUSION
The present research demonstrated the benefit of developed prediction model
in prediction of pCR in patients with rectal cancer. Our prediction nomogram
encompasses clinical and biological factors including tumor location, 
endoscopic finding, and 4 biomarkers, studied in a combination that helped to 
achieve high sensitivity and sufficient accuracy in prediction of a pCR. This 
finding stresses the importance of evaluation the mechanisms of cancer 
sensitivity to CRT as a complex, but not as separate processes of tumor cells 
proliferation, apoptosis, angiogenesis and others. We used the combination of 
biomarkers and morphometric findings that showed distinct patterns of 
expression and features between pCR and non-pCR to include in the 
prediction nomogram. Despite certain limitations of this study its major 
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advantage is demonstrating the utility of prediction nomogram in identifying 
patients more prone to be pCR and making treatment strategies.
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ABSTRACT (IN KOREAN) 
직장암의 수술 전 화학방사선요법 후 형태계측 변화와 바이오마커
발현을 이용한 병리학적 완전관해 예측 노모그램
<지도교수 김남규>
연세대학교 대학원 의학과
허혁
직장암의 수술 전 화학방사선요법 치료 후 병리학적 완전관해를
예측하기 위해 수 많은 분자 수준의 표지자와 영상학적 도구들이 사
용되어 왔다. 하지만 종양의 치료 반응 평가에 대한 명확한 결과를
보여주는 방법은 없었다. 본 연구의 목적은 관련 바이오마커 및 내
시경 소견을 분석함으로써 병리학적 완전관해를 예측하는 노모그램
을 제시하는 것이다. 종양 검체는 2011년 11월에서 2014년 4월 사이
수술 전 화학방사선요법을 시행 받기 전의 직장암 환자 120명으로부
터 전향적으로 채취되었다. 모든 환자는 수술 전 화학방사선요법 종
료 후 8주 뒤에 전직장간막 절제술로 근치적 수술을 받았다. 역전사
중합효소 연쇄반응 (RT-PCR) 분석을 통하여 신선 종양 검체로부터 7 
개의 바이오마커 (p53, p21, Ki-67, VEGF, CD133, CD24, CD44)의
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mRNA 발현 수준을 평가하였다. mRNA의 발현 정도는 GAPDH의 발현 정
도에 따라 교정 (목표 Ct – GAPDH Ct)하여 ΔCt로 나타내었다. 병리
학적으로 완전관해를 보이지 않은 검체의 mRNA에 대한 완전관해를
보인 검체의 mRNA의 상대적인 양은 두 검체의 2-ΔCt 값의 상대비로
계산하였다. 낮은 ΔCt와 높은 2-ΔCt 값은 mRNA의 발현 수준이 높다
는 것을 의미한다. 내시경 검사는 선행 항암방사선 치료 전과 후(선
행 항암방사선 치료 종료 후 4주 뒤)에 실시하였다. 내시경 검사를
통해 임상적으로 완전 관해를 판단한 기준은 육안적으로 종양이 보
이지 않고, 백색 반흔 혹은 적색 반흔이 남아있는 경우로 하였다. 
임상적 변수 또한 평가하였다. 병리학적 완전관해 예측모델을 구축
하기 위해 임상변수 및 생물학적 변수를 로지스틱 회기 모형을 이용
하여 단변량 및 다변량 분석을 시행하였다. 80명의 훈련 집합
(training set)에 대하여 노모그램 (Nomogram)을 개발하고 40명의
외부 검증 집합 (validation set)에서 검증을 시행하였다, 식별력과
검정력은 곡선하면적 (area under the curve, AUC)과 눈금측정평면
도 (calibration plot)을 이용해 측정하였다. 병리학적 완전관해는
24명 (30%)의 환자에서 관찰되었다. 7개의 바이오마커 중, 4개의 바
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이오마커 (p53, p21, Ki67, CD133)의 mRNA 발현 수준은 병리학적 완
전관해와 유의한 상관관계가 있었다. P53의 낮은 발현 및 또는 p21, 
Ki67, CD133의 높은 발현을 보이는 환자들에서 병리학적 완전관해율
이 유의하게 높았다. 수술 전 화학방사선요법 후 시행한 내시경 검
사 상 임상적인 완전관해를 보인 27명의 환자 가운데 병리적 완전관
해를 보인 환자는 17명 (63.0%)이었다. 종양의 위치가 낮은 환자들
이 종양이 직장의 중간부에 위치한 환자에 비하여 더 높은 병리적
완전관해율을 보였다 [19 (38.8%) vs. 5(16.1%), p = 0.031]. 로지
스틱 회기모형을 통해 종양의 위치, 수술 전 화학방사선요법 후의
내시경 소견, 4 개의 바이오마커 (p53, p21, Ki67, CD133)가 병리적
완전관해와 유의하게 상관관계가 있음을 확인하였다. 4 개의 바이오
마커, 수술 전 화학방사선요법 후의 내시경 소견 및 종양의 위치를
이용한 다변량 예측모델을 기반으로 구축한 노모그램 (nomogram)은
훈련 집합 (AUC=0.945) 및 검증 집합 (AUC=0.922) 내에서 양호한 식
별력을 보였다. 눈금측정평면도 (calibration plot)는 두 집합 모두
에서 실제 병리학적 완전관해와 예측된 병리학적 완전관해의 확률이
유의하게 일치하는 것을 보여주었다. 병리학적 완전관해를 예측하기
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위한 노모그램은 수술 전 화학방사선요법 후 병리학적 완전관해를
보여 수술 없이 경과 관찰을 하거나 괄약근 보존수술을 시행할 수
있는 대상환자를 선별하는데 도움을 줌으로써 치료 방침 결정에 매
우 유용하게 사용 될 수 있을 것이다.
-----------------------------------------------------------------------------------------------
핵심되는 말 : 직장암, 화학방사선요법, 병리학적 완전관해, 바이오
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